Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Asset Writedowns and Impairment (2025)

Sunshine Biopharma's Asset Writedowns and Impairment history spans 1 years, with the latest figure at $131788.0 for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $131788.0; the TTM value through Dec 2025 reached $1.7 million, changed N/A, while the annual FY2025 figure was $1.7 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment reached $131788.0 in Q4 2025 per SBFM's latest filing, down from $554650.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $1.1 million in Q2 2025 to a low of $131788.0 in Q4 2025.